Latest News
From the Journals
‘Real-world’ study finds treat-to-target benefits out to 5 years
DAS28 and HAQ scores improved in patients with early RA in daily clinical practice.
Latest News
Here comes bimekizumab, the newest IL-17 inhibitor
KAUAI, HAWAII – “If this holds up in phase 3, it’s going to be a new world for our patients and for us, ” said Craig L. Leonardi, MD.
From the Journals
Large-vessel vasculitis: More severe in HIV-infected patients
Large-vessel vasculitis was more severe in HIV-infected individuals.
From the Journals
Majority of lupus patients lack eye exam around the start of hydroxychloroquine
Sociodemographic variation seen in Medicaid population study.
Latest News
Rheumatologists target prior authorization, Stark Law as barriers to competition
The ACR responds to HHS’ request for information.
Feature
Congress extends CHIP, funds opioid crisis response following temporary shutdown
Bill also addressed controversial Medicare payment panel.
From the Journals
ACR sounds more welcoming tone in new biosimilars position paper
But in a related editorial Dr. Roy Fleischmann notes that there are still many concerns regarding biosimilars.
Conference Coverage
Get ready for certolizumab for psoriasis
KAUAI, HAWAII – Women of childbearing potential may prefer it.
From the Journals
CV risk factors go undiagnosed, untreated in many psoriatic patients
Study of more than 2,000 patients at eight centers in Canada, the United States, and Israel.
From the Journals
Macrophage activation syndrome’s impact in childhood SLE felt mostly early
MAS remains a concern for children with SLE, but many outcomes were not significantly different from those without the complication.
Latest News
Make a PEST of your psoriasis patients
KAUAI, HAWAII – Every psoriasis patient should complete the Psoriasis Epidemiology Screening Tool (PEST) for psoriatic arthritis annually.